Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases

BNCT wasproposedforthetreatmentofdiffuse,non-Resectabletumorsinthelung.Weperformedboron biodistribution studies with 5 administration protocols employing the boron carriers BPA and orGB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versusl ung. Absolute tumor boronconcentrationvalueswere therapeuticallyuseful(25–76ppm)for3protocols.DosimetriccalculationsindicatethatBNCTatRA-3 would bepotentially therapeutic without exceeding radiotolerance in the lung